Table 2:
Patient laboratory and CT imaging results
| Patients (n=12) | |
|---|---|
| Tetrahydrocannibidiol on urine toxicology screen | 8/9 (89%) |
| Median blood urea nitrogen concentration (mg/dL) | 11 (9·5–15) |
| Median creatinine concentration (mg/dL) | 0·77 (0·69–0·87) |
| Median white blood cell count on day 1 of hospital admission (thousands per μL) | 14·6 (8·8–17·7) |
| White blood cell count >10 (thousands per μL) | 8/12 (67%) |
| Median serum eosinophil count (thousands per μL) | 0·03 (0–0·1) |
| Median serum neutrophil count (thousands per μL) | 13·1 (7·3–16·9) |
| Median serum lymphocyte count (thousands per μL) | 0·91 (0·5–1·5) |
| Median platelet count (thousands per μL) | 308 (256–385·5) |
| Median CRP concentration (mg/dL) | 232 (149–347) |
| CRP concentration >10 (mg/dL) | 10/10 (100%) |
| Median erythrocyte sedimentation rate (mm/h) | 80·5 (1–130) |
| Erythrocyte sedimentation rate >15 (mm/h) | 5/6 (83%) |
| Median procalcitonin concentration (ng/ml) | 1·59 (0·08–4·43) |
| Procalcitonin concentration >0·09 (ng/mL) | 8/9 (89%) |
| Lactate dehydrogenase concentration (U/L) | 484 (248–601) |
| Antinuclear antibodies screen (negative) | 6/6 (100%) |
| Antineutrophil cytoplasmic antibody screen (negative) | 6/6 (100%) |
| Rheumatoid factor (negative) | 3/3 (100%) |
| Double-stranded DNA antibodies (negative) | 3/3 (100%) |
| Anti-smith DNA antibodies (negative) | 2/2 (100%) |
| Anti-Ro/anti-La antibodies (negative) | 3/3 (100%) |
| Anti-citrullinated protein antibodies (negative) | 3/3 (100%) |
| Median IgE concentration (mg/dL) | 81·67 (9–143) |
| Infection analyses | |
| Blood cultures (no growth) | 12/12 (100%) |
| Sputum cultures (no growth) | 3/3 (100%) |
| Urine cultures (no growth) | 2/3 (67%) |
| Legionella cultures (no growth) | 8/8 (100%) |
| Rhinovirus PCR (negative) | 9/9 (100%) |
| Adenovirus PCR (negative) | 9/9 (100%) |
| Metapneumovirus DNA PCR (negative) | 9/9 (100%) |
| Parainfluenza 1–4 PCR (negative) | 9/9 (100%) |
| Influenza A (negative) | 10/10 (100%) |
| Influenza B (negative) | 10/10 (100%) |
| Respiratory syncytial virus (negative) | 9/9 (100%) |
| HIV 1/2 Ag/AB (non-reactive) | 11/11 (100%) |
| Mycoplasma pneumoniae nucleic acid amplification test (negative) | 7/7 (100%) |
| Mycoplasma pneumoniae IgM (negative) | 0/1 (0%) |
| Strep pneumoniae urinary Ag (negative) | 12/12 (100%) |
| Legionella urinary Ag (negative) | 12 (100%) |
| Cryptococcal antigen (negative) | 2/2 (100%) |
| Histoplasma antigen (negative) | 4/4 (100%) |
| Aspergillus antigen (negative) | 3/3 (100%) |
| Pneumocystis DNA PCR (negative) | 4/4 (100%) |
| Stool studies (negative) | 3/3 (100%) |
| CT findings | 11/11 |
| Subpleural sparing | 7 (64%) |
| Bilateral ground glass opacification | 11 (100%) |
| Nodules | 0 |
| Pleural effusions | 1 (9%) |
| Fibrotic features (reticulation, bronchiectasis, honeycombing) | 2 (18%) |
| Ground glass opacification pattern | |
| Patchy | 7 (64%) |
| Confluent | 3 (27%) |
| Both | 1 (9%) |
| Mediastinal lymphadenopathy | 3 (27%) |
Median (IQR), n/N (%), or n (%). One patient did not have CT and had a chest x-ray instead.